ATP Citrate Lyase is a General Tumour Biomarker and Contributes to the Development of Cutaneous Squamous Cell Carcinoma

• DOI: 10.2340/actadv.v104.23805
• Publication Date: 2024-04-09T06:11:05Z
• Authors: Ruiting Luo; Yingjian Huang; Ruimin Bai; Meng Liu; Liang Sun; Xiaofei Wang; Yan Zheng
• Keywords: ATP citrate lyase; Lyase

ATP citrate lyase, the first rate-limiting enzyme in de novo lipogenesis, plays a crucial role tumour progression. This study explores lyase's potential as biomarker and its cutaneous squamous cell carcinoma. lyase expression patterns were analysed using TCGA TIMER databases, patient skin specimens collected for immunohistochemistry to determine levels. Cell proliferation, cycle, apoptosis, c-Myc assessed A431 SCL-1 cells. Stable lines with reduced obtained subcutaneously implanted into nude mice evaluate vivo growth. Ki67, TUNEL staining subcutaneous tumours. exhibited upregulation various tumours, showed significant associations prognosis immune infiltrate. Moreover, was highly expressed After silencing, carcinoma growth decelerated, cycle halted, apoptosis increased, decreased. Animal experiments revealed that, following knockdown, tissue slowed down, there reduction Ki-67 expression, accompanied by enhanced staining. In conclusion, may serve biomarker. It is therapeutic target.